Insomnia is characterized by severe difficulties in falling asleep and staying asleep. Acute insomnia is the most severe form of insomnia. It last for several days up to about a month and is very short-term. It is also known as adjustment insomnia since it usually is caused by a drastic change in environment or during stressful events. Some common causes for acute insomnia are as follow: Cognitive Behavioral Therapy (CBT) is an effective form of treatment for insomnia. Cognitive behavioral therapy is also effective in treating minor forms of insomnia. It can also be used as additional treatment after medication or alternative therapy. Another way of treating insomnia is through medications and lifestyle changes.
Request Free Sample Copy With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-sample/958
According to a study by University of Laval, 2011, about 40 % of the adult Canadian are experiencing one or more symptoms of insomnia. Further, a latest research reported in Nature, 2017, stated that insomnia increases the risk in women to deliver premature babies by 30%. Increase in incidence of insomnia across the globe will propel the insomnia therapeutics market.
Advent of improved therapy with lesser side effects to drive the insomnia therapeutics market growth globally
Benzodiazepines (BZP) such as temazepam and diazepam are the commonly prescribed medication for insomnia. Though these medications are effective, prolonged use of these drugs may cause cognitive impairment, dependency and addiction. The launch of novel drugs such as Intermezzo (2014), tasimelteon (2014) have created a meteoric growth in G7 countries in the insomnia therapeutics and is expected market over the forecast period.
Intermezzo (2014), are used in small doses and administered under the tongue for faster absorption. Tesimelton approved by FDA in 2014 is the only drug approved by FDA for Non-24-Hour Sleep-Wake Rhythm Disorder and it lacks abuse potential. These products are expected to drive the insomnia therapeutics market over the forecast period.
Growing awareness and number of people seeking treatment for insomnia are expected to further contribute to the growth of the market. On the other hand, the loss of exclusivity of the drugs led the market more genericized, which is offering a competitive environment for new players. For instance, non-benzodiazepines and low dose sedating anti-depressants, still considered as a first line of medication for the insomnia, are facing stiff competition from the generics.
Request PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/958
According to a report by Sleep Research Society, 2012, 20% of the general adult population in Canada and U.S is suffering from insomnia and this number is expected to increase in the near future. Problems such as daytime sleepiness, and fatigue is affecting larger number of population and posing a considerable burden on these regions. All these factors will positively impact growth of the insomnia therapeutics market growth in the future period.
Insomnia therapeutics Market Taxonomy
By Drug Class
- Non benzodiazepines
By Distribution Channel
- Retail & Hospital Pharmacies
- Online Pharmacies
Rapid entry of new players to have positive impact on the global insomnia therapeutics market
Increasing entry of new players and new devices for insomnia is expected to foster growth of the market. FDA approved new device Cerêve Sleep System for insomnia in 2016 this device is used to reduce latency to stage 1 and stage 2 sleep by keeping the forehead cool. Major players in insomnia therapeutics market are GlaxoSmithKline plc, UCB Group, Otsuka Holdings Co., Ligand Pharmaceuticals Incorporated, Axxonis Pharma AG, Kyowa Hakko Kirin Co. Ltd., National Institute of Neurological Disorders and Stroke, Jazz Pharmaceuticals, Inc. Ltd., Omeros Corporation and Manhattan Pharmaceuticals, Inc.
𝐂𝐡𝐫𝐢𝐬𝐭𝐦𝐚𝐬 𝐒𝐚𝐥𝐞 𝐈𝐬 𝐋𝐢𝐯𝐞
𝐁𝐮𝐲 𝐍𝐨𝐰 𝐓𝐎 𝐀𝐯𝐚𝐢𝐥 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐅𝐫𝐨𝐦 𝟐𝟓-𝟑𝟎% 𝐓𝐢𝐥𝐥 𝟑𝟏-𝐃𝐞𝐜-𝟐𝟎𝟐𝟏
Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/958
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Insomnia therapeutics Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Insomnia therapeutics Industry Impact
Chapter 2 Insomnia therapeutics Competition by Types, Applications, and Top Regions and Countries
2.1 Insomnia therapeutics (Volume and Value) by Type
2.3 Insomnia therapeutics (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Insomnia therapeutics Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Insomnia therapeutics Market Analysis
Chapter 6 East Asia Insomnia therapeutics Market Analysis
Chapter 7 Europe Insomnia therapeutics Market Analysis
Chapter 8 South Asia Insomnia therapeutics Market Analysis
Chapter 9 Southeast Asia Insomnia therapeutics Market Analysis
Chapter 10 Middle East Insomnia therapeutics Market Analysis
Chapter 11 Africa Insomnia therapeutics Market Analysis
Chapter 12 Oceania Insomnia therapeutics Market Analysis
Chapter 13 South America Insomnia therapeutics Market Analysis
Chapter 14 Company Profiles and Key Figures in Insomnia therapeutics Business
Chapter 15 Insomnia therapeutics Market Forecast (2021-2027)
Chapter 16 Conclusions
Related Market Intelligence Reports:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Senior Client Partner – Business Development
Coherent Market Insights